Advancing Innovative Therapies for
Rare Diseases and Serious Fungal Infections.

Innovative Science: Advancing a Differentiated Pipeline

SCYNEXIS is advancing innovative therapies for diseases with significant unmet medical need.

SCY-770 is being developed for autosomal dominant polycystic kidney disease (ADPKD), with potential expansion into additional indications where AMPK activation may provide meaningful therapeutic benefit.

SCY-247, a second-generation fungerp, is part of SCYNEXIS differentiated antifungal portfolio targeting treatment and prevention of serious and difficult-to-treat fungal infections

A Focused Portfolio Built on Validated Biology

Program
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
SCY-770
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCY-247*
Treatment and Prevention of Invasive Fungal Infections
Fungerp analogs**
Treatment of resistant fungi with novel structural analogs
Brexafemme
VVC and Recurrent VVC
Partnered with
Approved



* This project has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Center for the Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50126C00007

**Development up to IND funded by NIH via a CETR grant of ~$7M

A Pipeline Grounded in Science and Purpose

From rare kidney disease to serious fungal infections, our programs apply proven biology in pursuit of transformative therapies for patients with limited treatment options.

Explore SCY-770
Explore SCY-247